0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Viral Vectors Gene Therapy Market Research Report 2022
Published Date: August 2022
|
Report Code: QYRE-Auto-23K11342
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Viral Vectors Gene Therapy Market Research Report 2022

Global Viral Vectors Gene Therapy Market Research Report 2022

Code: QYRE-Auto-23K11342
Report
August 2022
93 Pages
QYResearch
Region: Global
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
Highlights

The global Viral Vectors Gene Therapy market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Viral Vectors Gene Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Viral Vectors Gene Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Viral Vectors Gene Therapy in In Vivo is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Viral Vectors Gene Therapy include Amgen, Novartis, Orchard Therapeutics, Spark Therapeutics, Agc Biologics, Anges, Bluebird Bio, Jazz Pharmaceuticals and Dynavax Technologies, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Retro Viral Vectors, which accounted for % of the global market of Viral Vectors Gene Therapy in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vectors Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors Gene Therapy.
The Viral Vectors Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Viral Vectors Gene Therapy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
Product Type Insights
Global markets are presented by Viral Vectors Gene Therapy type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Viral Vectors Gene Therapy are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Viral Vectors Gene Therapy segment by Type

Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Viral Vectors Gene Therapy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Viral Vectors Gene Therapy market.

Viral Vectors Gene Therapy Segment by Application

In Vivo
Ex Vivo
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Viral Vectors Gene Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Viral Vectors Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Viral Vectors Gene Therapy industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors Gene Therapy.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vectors Gene Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Retro Viral Vectors
1.2.3 Adeno-associated Virus Vectors
1.2.4 Other Viral Vectors
1.3 Market by Application
1.3.1 Global Viral Vectors Gene Therapy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 In Vivo
1.3.3 Ex Vivo
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Viral Vectors Gene Therapy Market Perspective (2017-2028)
2.2 Viral Vectors Gene Therapy Growth Trends by Region
2.2.1 Viral Vectors Gene Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Viral Vectors Gene Therapy Historic Market Size by Region (2017-2022)
2.2.3 Viral Vectors Gene Therapy Forecasted Market Size by Region (2023-2028)
2.3 Viral Vectors Gene Therapy Market Dynamics
2.3.1 Viral Vectors Gene Therapy Industry Trends
2.3.2 Viral Vectors Gene Therapy Market Drivers
2.3.3 Viral Vectors Gene Therapy Market Challenges
2.3.4 Viral Vectors Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vectors Gene Therapy Players by Revenue
3.1.1 Global Top Viral Vectors Gene Therapy Players by Revenue (2017-2022)
3.1.2 Global Viral Vectors Gene Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Viral Vectors Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Viral Vectors Gene Therapy Revenue
3.4 Global Viral Vectors Gene Therapy Market Concentration Ratio
3.4.1 Global Viral Vectors Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors Gene Therapy Revenue in 2021
3.5 Viral Vectors Gene Therapy Key Players Head office and Area Served
3.6 Key Players Viral Vectors Gene Therapy Product Solution and Service
3.7 Date of Enter into Viral Vectors Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vectors Gene Therapy Breakdown Data by Type
4.1 Global Viral Vectors Gene Therapy Historic Market Size by Type (2017-2022)
4.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2023-2028)
5 Viral Vectors Gene Therapy Breakdown Data by Application
5.1 Global Viral Vectors Gene Therapy Historic Market Size by Application (2017-2022)
5.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Viral Vectors Gene Therapy Market Size (2017-2028)
6.2 North America Viral Vectors Gene Therapy Market Size by Country (2017-2022)
6.3 North America Viral Vectors Gene Therapy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Viral Vectors Gene Therapy Market Size (2017-2028)
7.2 Europe Viral Vectors Gene Therapy Market Size by Country (2017-2022)
7.3 Europe Viral Vectors Gene Therapy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vectors Gene Therapy Market Size (2017-2028)
8.2 Asia-Pacific Viral Vectors Gene Therapy Market Size by Country (2017-2022)
8.3 Asia-Pacific Viral Vectors Gene Therapy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Viral Vectors Gene Therapy Market Size (2017-2028)
9.2 Latin America Viral Vectors Gene Therapy Market Size by Country (2017-2022)
9.3 Latin America Viral Vectors Gene Therapy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vectors Gene Therapy Market Size (2017-2028)
10.2 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2017-2022)
10.3 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Viral Vectors Gene Therapy Introduction
11.1.4 Amgen Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.1.5 Amgen Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Viral Vectors Gene Therapy Introduction
11.2.4 Novartis Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Orchard Therapeutics
11.3.1 Orchard Therapeutics Company Detail
11.3.2 Orchard Therapeutics Business Overview
11.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Introduction
11.3.4 Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.3.5 Orchard Therapeutics Recent Development
11.4 Spark Therapeutics
11.4.1 Spark Therapeutics Company Detail
11.4.2 Spark Therapeutics Business Overview
11.4.3 Spark Therapeutics Viral Vectors Gene Therapy Introduction
11.4.4 Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.4.5 Spark Therapeutics Recent Development
11.5 Agc Biologics
11.5.1 Agc Biologics Company Detail
11.5.2 Agc Biologics Business Overview
11.5.3 Agc Biologics Viral Vectors Gene Therapy Introduction
11.5.4 Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.5.5 Agc Biologics Recent Development
11.6 Anges
11.6.1 Anges Company Detail
11.6.2 Anges Business Overview
11.6.3 Anges Viral Vectors Gene Therapy Introduction
11.6.4 Anges Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.6.5 Anges Recent Development
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Detail
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Viral Vectors Gene Therapy Introduction
11.7.4 Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.7.5 Bluebird Bio Recent Development
11.8 Jazz Pharmaceuticals
11.8.1 Jazz Pharmaceuticals Company Detail
11.8.2 Jazz Pharmaceuticals Business Overview
11.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Introduction
11.8.4 Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.8.5 Jazz Pharmaceuticals Recent Development
11.9 Dynavax Technologies
11.9.1 Dynavax Technologies Company Detail
11.9.2 Dynavax Technologies Business Overview
11.9.3 Dynavax Technologies Viral Vectors Gene Therapy Introduction
11.9.4 Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.9.5 Dynavax Technologies Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Viral Vectors Gene Therapy Introduction
11.10.4 Biogen Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.10.5 Biogen Recent Development
11.11 Sarepta Therapeutics
11.11.1 Sarepta Therapeutics Company Detail
11.11.2 Sarepta Therapeutics Business Overview
11.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Introduction
11.11.4 Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.11.5 Sarepta Therapeutics Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Detail
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Viral Vectors Gene Therapy Introduction
11.12.4 Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2017-2022)
11.12.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Viral Vectors Gene Therapy Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Retro Viral Vectors
    Table 3. Key Players of Adeno-associated Virus Vectors
    Table 4. Key Players of Other Viral Vectors
    Table 5. Global Viral Vectors Gene Therapy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Viral Vectors Gene Therapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Viral Vectors Gene Therapy Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Viral Vectors Gene Therapy Market Share by Region (2017-2022)
    Table 9. Global Viral Vectors Gene Therapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Viral Vectors Gene Therapy Market Share by Region (2023-2028)
    Table 11. Viral Vectors Gene Therapy Market Trends
    Table 12. Viral Vectors Gene Therapy Market Drivers
    Table 13. Viral Vectors Gene Therapy Market Challenges
    Table 14. Viral Vectors Gene Therapy Market Restraints
    Table 15. Global Viral Vectors Gene Therapy Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Viral Vectors Gene Therapy Market Share by Players (2017-2022)
    Table 17. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2021)
    Table 18. Ranking of Global Top Viral Vectors Gene Therapy Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Viral Vectors Gene Therapy Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Viral Vectors Gene Therapy Product Solution and Service
    Table 22. Date of Enter into Viral Vectors Gene Therapy Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Viral Vectors Gene Therapy Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2017-2022)
    Table 26. Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2023-2028)
    Table 28. Global Viral Vectors Gene Therapy Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2017-2022)
    Table 30. Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2023-2028)
    Table 32. North America Viral Vectors Gene Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Viral Vectors Gene Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Viral Vectors Gene Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Viral Vectors Gene Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Viral Vectors Gene Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Viral Vectors Gene Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Amgen Company Detail
    Table 43. Amgen Business Overview
    Table 44. Amgen Viral Vectors Gene Therapy Product
    Table 45. Amgen Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 46. Amgen Recent Development
    Table 47. Novartis Company Detail
    Table 48. Novartis Business Overview
    Table 49. Novartis Viral Vectors Gene Therapy Product
    Table 50. Novartis Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 51. Novartis Recent Development
    Table 52. Orchard Therapeutics Company Detail
    Table 53. Orchard Therapeutics Business Overview
    Table 54. Orchard Therapeutics Viral Vectors Gene Therapy Product
    Table 55. Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 56. Orchard Therapeutics Recent Development
    Table 57. Spark Therapeutics Company Detail
    Table 58. Spark Therapeutics Business Overview
    Table 59. Spark Therapeutics Viral Vectors Gene Therapy Product
    Table 60. Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 61. Spark Therapeutics Recent Development
    Table 62. Agc Biologics Company Detail
    Table 63. Agc Biologics Business Overview
    Table 64. Agc Biologics Viral Vectors Gene Therapy Product
    Table 65. Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 66. Agc Biologics Recent Development
    Table 67. Anges Company Detail
    Table 68. Anges Business Overview
    Table 69. Anges Viral Vectors Gene Therapy Product
    Table 70. Anges Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 71. Anges Recent Development
    Table 72. Bluebird Bio Company Detail
    Table 73. Bluebird Bio Business Overview
    Table 74. Bluebird Bio Viral Vectors Gene Therapy Product
    Table 75. Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 76. Bluebird Bio Recent Development
    Table 77. Jazz Pharmaceuticals Company Detail
    Table 78. Jazz Pharmaceuticals Business Overview
    Table 79. Jazz Pharmaceuticals Viral Vectors Gene Therapy Product
    Table 80. Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 81. Jazz Pharmaceuticals Recent Development
    Table 82. Dynavax Technologies Company Detail
    Table 83. Dynavax Technologies Business Overview
    Table 84. Dynavax Technologies Viral Vectors Gene Therapy Product
    Table 85. Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 86. Dynavax Technologies Recent Development
    Table 87. Biogen Company Detail
    Table 88. Biogen Business Overview
    Table 89. Biogen Viral Vectors Gene Therapy Product
    Table 90. Biogen Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 91. Biogen Recent Development
    Table 92. Sarepta Therapeutics Company Detail
    Table 93. Sarepta Therapeutics Business Overview
    Table 94. Sarepta Therapeutics Viral Vectors Gene TherapyProduct
    Table 95. Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 96. Sarepta Therapeutics Recent Development
    Table 97. Gilead Sciences Company Detail
    Table 98. Gilead Sciences Business Overview
    Table 99. Gilead Sciences Viral Vectors Gene TherapyProduct
    Table 100. Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2017-2022) & (US$ Million)
    Table 101. Gilead Sciences Recent Development
    Table 102. Research Programs/Design for This Report
    Table 103. Key Data Information from Secondary Sources
    Table 104. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Viral Vectors Gene Therapy Market Share by Type: 2021 VS 2028
    Figure 2. Retro Viral Vectors Features
    Figure 3. Adeno-associated Virus Vectors Features
    Figure 4. Other Viral Vectors Features
    Figure 5. Global Viral Vectors Gene Therapy Market Share by Application in 2021 & 2028
    Figure 6. In Vivo Case Studies
    Figure 7. Ex Vivo Case Studies
    Figure 8. Viral Vectors Gene Therapy Report Years Considered
    Figure 9. Global Viral Vectors Gene Therapy Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 10. Global Viral Vectors Gene Therapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Viral Vectors Gene Therapy Market Share by Region: 2021 VS 2028
    Figure 12. Global Viral Vectors Gene Therapy Market Share by Players in 2021
    Figure 13. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2021)
    Figure 14. The Top 10 and 5 Players Market Share by Viral Vectors Gene Therapy Revenue in 2021
    Figure 15. North America Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 16. North America Viral Vectors Gene Therapy Market Share by Country (2017-2028)
    Figure 17. United States Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. Canada Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Europe Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Viral Vectors Gene Therapy Market Share by Country (2017-2028)
    Figure 21. Germany Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. France Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. U.K. Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Italy Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Russia Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Nordic Countries Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Asia-Pacific Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Viral Vectors Gene Therapy Market Share by Region (2017-2028)
    Figure 29. China Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Japan Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. South Korea Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Southeast Asia Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. India Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Australia Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Latin America Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Viral Vectors Gene Therapy Market Share by Country (2017-2028)
    Figure 37. Mexico Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Brazil Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Middle East & Africa Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Viral Vectors Gene Therapy Market Share by Country (2017-2028)
    Figure 41. Turkey Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Saudi Arabia Viral Vectors Gene Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Amgen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 44. Novartis Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 45. Orchard Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 46. Spark Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 47. Agc Biologics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 48. Anges Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 49. Bluebird Bio Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 50. Jazz Pharmaceuticals Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 51. Dynavax Technologies Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 52. Biogen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 53. Sarepta Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 54. Gilead Sciences Revenue Growth Rate in Viral Vectors Gene Therapy Business (2017-2022)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
    Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$2900
This license allows only one user to access the PDF.

Electronic (PDF)
$4350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$5800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Bioinformatics Barcelona
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Add to Cart

Global Human Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Human Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-476
Thu Sep 22 00:00:00 UTC 2022

Add to Cart

Global Vaccine Carriers Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Vaccine Carriers Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-618
Wed Sep 21 00:00:00 UTC 2022

Add to Cart

Global DNA Vaccines Market Size Manufacturers Supply Chain Sales Channel and Clients 2022 2028
Global DNA Vaccines Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-4I12362
Tue Sep 20 00:00:00 UTC 2022

Add to Cart